PTAB denies Novartis petitions to review Plexxikon patents

21-01-2019

PTAB denies Novartis petitions to review Plexxikon patents

fstop123 / iStockphoto.com

The US Patent and Trademark Office (USPTO) has declined to hear two petitions filed by Switzerland-based Novartis to review two patents owned by drug discovery company Plexxikon.


Novartis, Plexxikon, cancer treatment, melanoma, Zelboraf, US Patent and Trademark Office, Patent Trial and Appeal Board, patent infringement

LSIPR